WO2000043505A3 - Protease - Google Patents

Protease Download PDF

Info

Publication number
WO2000043505A3
WO2000043505A3 PCT/EP2000/000390 EP0000390W WO0043505A3 WO 2000043505 A3 WO2000043505 A3 WO 2000043505A3 EP 0000390 W EP0000390 W EP 0000390W WO 0043505 A3 WO0043505 A3 WO 0043505A3
Authority
WO
WIPO (PCT)
Prior art keywords
aspartate
protease
radicals
catalytically active
active structure
Prior art date
Application number
PCT/EP2000/000390
Other languages
German (de)
English (en)
Other versions
WO2000043505A2 (fr
Inventor
Kay Hofmann
Original Assignee
Memorec Medical Molecular Res
Kay Hofmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19902550A external-priority patent/DE19902550A1/de
Application filed by Memorec Medical Molecular Res, Kay Hofmann filed Critical Memorec Medical Molecular Res
Priority to EP00903587A priority Critical patent/EP1144603A3/fr
Priority to AU25421/00A priority patent/AU2542100A/en
Priority to CA002360585A priority patent/CA2360585A1/fr
Publication of WO2000043505A2 publication Critical patent/WO2000043505A2/fr
Publication of WO2000043505A3 publication Critical patent/WO2000043505A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Catalysts (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une protéase comportant deux restes aspartate dans une structure catalytiquement active, un premier reste aspartate se situant dans un motif X1GX2GD et un deuxième reste aspartate se situant dans un motif X3X4DX5. La protéase selon l'invention est caractérisée en ce que X1, X2, X3 et X5 pouvent être choisis indépendamment les uns des autres parmi Ala, Val, Leu, Met et Ile, en ce que X4 est un acide aminé aromatique et en ce que les motifs X1GX2GD et X3X4DX5 se situent dans une région transmembranaire.
PCT/EP2000/000390 1999-01-22 2000-01-19 Protease WO2000043505A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00903587A EP1144603A3 (fr) 1999-01-22 2000-01-19 Protease
AU25421/00A AU2542100A (en) 1999-01-22 2000-01-19 Protease
CA002360585A CA2360585A1 (fr) 1999-01-22 2000-01-19 Protease

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE19902550.9 1999-01-22
DE19902550A DE19902550A1 (de) 1999-01-22 1999-01-22 Aspartatprotease
DE19925946 1999-06-08
DE19925946.1 1999-06-08
DE19929115.2 1999-06-24
DE19929115 1999-06-24

Publications (2)

Publication Number Publication Date
WO2000043505A2 WO2000043505A2 (fr) 2000-07-27
WO2000043505A3 true WO2000043505A3 (fr) 2001-11-29

Family

ID=27218935

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/000390 WO2000043505A2 (fr) 1999-01-22 2000-01-19 Protease

Country Status (4)

Country Link
EP (1) EP1144603A3 (fr)
AU (1) AU2542100A (fr)
CA (1) CA2360585A1 (fr)
WO (1) WO2000043505A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887677B1 (en) 1999-07-12 2005-05-03 Trustees Of Dartmouth College Compounds and methods for identifying compounds which inhibit a new class of aspartyl proteases
US8609087B2 (en) 1999-07-12 2013-12-17 Trustees Of Dartmouth College Compounds and methods for identifying compounds which inhibit a new class of aspartyl proteases
GB0126782D0 (en) * 2001-11-07 2002-01-02 Medical Res Council Assay

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033916A2 (fr) * 1997-01-31 1998-08-06 Genetics Institute, Inc. Proteines secretees et polynucleotides codant celles-ci
WO1998040404A2 (fr) * 1997-03-11 1998-09-17 Genetics Institute, Inc. Proteines secretees et polynucleotides codant ces dernieres
WO1999003990A1 (fr) * 1997-07-16 1999-01-28 Human Genome Sciences, Inc. Serie de 64 proteines humaines secretees
WO1999033873A1 (fr) * 1997-12-26 1999-07-08 Ono Pharmaceutical Co. Ltd. NOUVEAUX POLYPEPTIDES, ADNc CODANT CES POLYPEPTIDES ET UTILISATION DE CEUX-CI
WO1999043693A1 (fr) * 1998-02-26 1999-09-02 Human Genome Sciences, Inc. Proteines secretees par l'homme
WO2000017222A1 (fr) * 1998-09-23 2000-03-30 Human Genome Sciences, Inc. 31 proteines humaines secretees

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033916A2 (fr) * 1997-01-31 1998-08-06 Genetics Institute, Inc. Proteines secretees et polynucleotides codant celles-ci
WO1998040404A2 (fr) * 1997-03-11 1998-09-17 Genetics Institute, Inc. Proteines secretees et polynucleotides codant ces dernieres
WO1999003990A1 (fr) * 1997-07-16 1999-01-28 Human Genome Sciences, Inc. Serie de 64 proteines humaines secretees
WO1999033873A1 (fr) * 1997-12-26 1999-07-08 Ono Pharmaceutical Co. Ltd. NOUVEAUX POLYPEPTIDES, ADNc CODANT CES POLYPEPTIDES ET UTILISATION DE CEUX-CI
EP1043333A1 (fr) * 1997-12-26 2000-10-11 Ono Pharmaceutical Co., Ltd. NOUVEAUX POLYPEPTIDES, ADNc CODANT CES POLYPEPTIDES ET UTILISATION DE CEUX-CI
WO1999043693A1 (fr) * 1998-02-26 1999-09-02 Human Genome Sciences, Inc. Proteines secretees par l'homme
WO2000017222A1 (fr) * 1998-09-23 2000-03-30 Human Genome Sciences, Inc. 31 proteines humaines secretees

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENEMBL 1 August 1998 (1998-08-01), LAMERDIN ET AL: "FOS39554_1", XP002141740 *
DATABASE GENEMBL 8 August 1996 (1996-08-08), HILLIER ET AL.: "zc51b02.r1 Soares senescentr fibroblasts NbHSF Homo sapiens cDNA clone IMAGE:325803", XP002157596 *

Also Published As

Publication number Publication date
WO2000043505A2 (fr) 2000-07-27
EP1144603A3 (fr) 2002-02-06
EP1144603A2 (fr) 2001-10-17
AU2542100A (en) 2000-08-07
CA2360585A1 (fr) 2000-07-27

Similar Documents

Publication Publication Date Title
EP1803733A3 (fr) Traitement de l'inflammation
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
WO2006014570A3 (fr) Compositions peptidiques amphiphiles purifiees et utilisations de celles-ci
WO2003079972A3 (fr) Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs
WO2003011115A3 (fr) Agents de contraste multimères ciblés à base de peptides
WO2000054813A3 (fr) Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prévention des maladies de l'oeil
DK0720482T3 (da) Prosaposin og cytokin-afledte peptider som terapeutiske midler
HK1056576A1 (en) Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity
ZA200107978B (en) Low-molecular inhibitors of complement proteases.
PL322179A1 (en) Hydroxyethylaminosulphonamides of heterocyclocarbonylamino acids as inhibitors of retroviral protease
WO2009025116A1 (fr) Peptide cdh3 et agent médicinal le comprenant
WO1999037678A3 (fr) Peptides antimicrobiens
WO2003048205A3 (fr) Proteines a activite inhibitrice de l'il-6
EP0828003A3 (fr) Sérine protéase humaine
WO2000075173A3 (fr) Peptides
AU2003286404A1 (en) Peptide nanostructures, methods for their preparation and use
WO2000043505A3 (fr) Protease
WO1995020663A3 (fr) VARIANTS THERMOSTABLES DE PROTEASES NEUTRES DE BACILLUS STEAROTHERMOPHILUS ET DE $i(BACILLUS THERMOPROTEOLYTICUS)
WO2003070751A3 (fr) Mimetiques peptidiques partiels et procedes associes
EP1382612A4 (fr) Proteine participant a la restauration de fertilite de la sterilite male cytoplasmique et gene codant ladite proteine
AU2003290259A1 (en) Peptides impairing pbx dependent gene regulation
WO2003006492A3 (fr) Peptides exerçant une activite biologique
EP2143730A3 (fr) Peptides modifiés et leur utilisation pour le traitement des maladies auto-immunes
CO4870706A1 (es) Metodo mejorado para la modificacion de polipeptidos en vias de purificacion
AU2640299A (en) Genomic gene encoding hm1.24 antigen protein and promoter thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000903587

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2360585

Country of ref document: CA

Ref country code: CA

Ref document number: 2360585

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000903587

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000903587

Country of ref document: EP